Intracranial Hemorrhage Diagnosis & Treatment Market Research Report—Forecast to 2027

Intracranial Hemorrhage Diagnosis & Treatment Market Research Report—Forecast to 2027

$4450 – $6250

Global Intracranial Hemorrhage Diagnosis & Treatment Market is expected to witness a CAGR of 5.98% during the research period of 2020 to 2027. Intracranial hemorrhage is intense bleeding inside the skull or brain which results in a life-threatening emergency.

SKU: MRFR210104 Category: Tags: , , , , , , , , , , , , , , ,

Description

Intracranial Hemorrhage Diagnosis & Treatment Market Research Report—Forecast to 2027

Intracranial Hemorrhage Diagnosis & Treatment Market Overview

Global Intracranial Hemorrhage Diagnosis & Treatment Market is expected to witness a CAGR of 5.98% during the research period of 2020 to 2027. Intracranial hemorrhage is intense bleeding inside the skull or brain which results in a life-threatening emergency. lead to an increase in intracranial pressure, which can further damage brain tissues. The global market growth is mainly attributed to the rising prevalence of aneurysms, the growing number of road accidents, and the rising expenditure on healthcare infrastructure. Furthermore, the increased funding for the research and treatment of intracranial hemorrhage drives the growth of the market.

The Global Intracranial Hemorrhage Diagnosis & Treatment Market is anticipated to register a healthy market growth owing to the largest market value of USD 1,493.98 Million in 2019. Additionally, the geriatric population and age-related brain disorders also raise the number of patients in need of diagnostic tools required for assessing the types of hemorrhage. However, the rising availability of counterfeit drugs & complications associated with the surgery and lack of awareness about the available treatments is expected to restrain the growth of the global market during the review period.

Market Segmentation
Global Intracranial Hemorrhage Diagnosis & Treatment Market has been classified into Type and Diagnosis & Treatment.
Based on product segment, the market has been classified into an intracerebral hemorrhage, subarachnoid hemorrhage, epidural hematoma, and subdural hematoma.

In terms of diagnosis & treatment segment, the intracranial hemorrhage diagnosis & treatment market has been divided into diagnosis and treatment. The diagnosis segment has been further divided into CT, MRI, and others. The treatment segment has been further bifurcated into medication and surgery. In terms of medication type, the global market is further classified into anti-hypertensive drugs, coagulants, and others. However, based on surgery, the market is further classified as decompression surgery, craniotomy with open surgery, endoscopic evacuation, stereotactic aspiration, and clipping or coiling procedures.

Regional Analysis
Geographically, the Global Intracranial Hemorrhage Diagnosis & Treatment Market has been segmented into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is expected to contribute the largest share of the global intracranial hemorrhage diagnosis & treatment market during the review period. The regional market is attributed to the well-established healthcare sector, increased expenditure on research, rapid adoption of advanced treatment, and the presence of leading players in the region.
The European market is anticipated to exhibit the second largest market due to the advanced treatment facilities, rising government initiatives to promote research, rising number of trauma cases, and increasing number healthcare spending. Asia-Pacific is anticipated to register substantial market growth during the review period. The regional market growth is attributed to the rising R&D funding by developing countries such as China and India for the development of the healthcare infrastructure.

Major Players
The Key Players in the Global Intracranial Hemorrhage Diagnosis & Treatment Market include Canon Inc. (Japan), FUJIFILM Holdings Corporation (Japan), GE Healthcare (US), Hitachi Ltd. (Japan), Infrascan, inc. (US), Johnson & Johnson (US), Koninklijke Philips N.V. (Netherlands), Medtronic plc (Ireland), Siemens AG (Germany), Stryker Corporation (US) and Others.

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Intracranial Hemorrhage Diagnosis & Treatment Market Research Report—Forecast to 2027

Patient Monitoring Devices Market By Type (Hemodynamic Monitoring, Neuromonitoring, Cardiac Monitoring, Fetal & Neonatal Monitoring, Respiratory Monitoring, Multi-Parameter Monitoring, Remote Patient Monitoring, Weigh Monitoring, And Temperature Monitoring Devices); By End User (Hospitals & Clinics, Home Settings, and Ambulatory Surgical Centers); and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 17 2.2 RESEARCH OBJECTIVE 17 2.3 MARKET STRUCTURE 17 2.4 ASSUMPTIONS & LIMITATIONS 18 3 RESEARCH METHODOLOGY 3.1 DATA MINING 19 3.2 SECONDARY RESEARCH 20 3.3 PRIMARY RESEARCH 21 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 22 3.5 FORECASTING TECHNIQUES 23 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 24 3.6.1 BOTTOM-UP APPROACH 25 3.6.2 TOP-DOWN APPROACH 25 3.7 DATA TRIANGULATION 26 3.8 VALIDATION 26 4 MARKET DYNAMICS 4.1 OVERVIEW 27 4.2 DRIVERS 29 4.2.1 LARGE NUMBER OF PATIENTS SUFFERING FROM BRAIN CANCER, ANEURYSM, AND RELATED CONDITIONS 29 4.2.2 GROWING NUMBER OF INCIDENCES OF TRAUMA AND ACCIDENTS LEADING TO TRAUMATIC BRAIN INJURY (TBI) 29 4.2.3 CLINICAL TRIALS TO IMPROVE AVAILABLE TREATMENTS 30 4.2.4 INCREASING HEALTHCARE EXPENDITURE 30 4.3 RESTRAINTS 31 4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE TREATMENT 31 4.3.2 LACK OF SKILLED WORKFORCE 32 4.4 OPPORTUNITIES 33 4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS 33 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 34 5.1.1 R&D 35 5.1.2 MANUFACTURING 35 5.1.3 DISTRIBUTION AND SALES 35 5.1.4 POST-SALES MONITORING 35 5.2 PORTER’S FIVE FORCES MODEL 36 5.2.1 BARGAINING POWER OF SUPPLIERS 37 5.2.2 BARGAINING POWER OF BUYERS 37 5.2.3 THREAT OF NEW ENTRANTS 37 5.2.4 THREAT OF SUBSTITUTES 37 5.2.5 INTENSITY OF RIVALRY 37 5.3 COVID-19 IMPACT ANALYSIS 38 5.3.1 IMPACT ON GROWTH RATE 38 6 GLOBAL INTRACRANIAL HEMORRHAGE DIAGNOSIS & TREATMENT MARKET, BY TYPE 6.1 OVERVIEW 39 6.2 INTRACEREBRAM HEMORRHAGE 40 6.3 SUBARACHNOID HEMORRHAGE 40 6.4 EPIDURAL HEMATOMA 41 6.5 SUBDURAL HEMATOMA 41 7 GLOBAL INTRACRANIAL HEMORRHAGE DIAGNOSIS & TREATMENT MARKET, BY DIAGNOSIS & TREATMENT 7.1 OVERVIEW 42 7.2 DIAGNOSIS 43 7.3 TREATMENT 44 8 GLOBAL INTRACRANIAL HEMORRHAGE DIAGNOSIS & TREATMENT MARKET, BY REGION 8.1 OVERVIEW 46 8.2 AMERICAS 47 8.2.1 NORTH AMERICA 50 8.2.1.1 US 53 8.2.1.2 CANADA 56 8.2.2 LATIN AMERICA 58 8.3 EUROPE 60 8.3.1 WESTERN EUROPE 63 8.3.1.1 GERMANY 66 8.3.1.2 FRANCE 68 8.3.1.3 UK 70 8.3.1.4 ITALY 72 8.3.1.5 SPAIN 74 8.3.1.6 REST OF WESTERN EUROPE 76 8.3.2 EASTERN EUROPE 78 8.4 ASIA-PACIFIC 80 8.4.1 CHINA 83 8.4.2 JAPAN 85 8.4.3 INDIA 87 8.4.4 AUSTRALIA 89 8.4.5 SOUTH KOREA 91 8.4.6 REST OF ASIA-PACIFIC 93 8.5 MIDDLE EAST & AFRICA 96 8.5.1 MIDDLE EAST 99 8.5.2 AFRICA 101 9 COMPETITIVE LANDSCAPE 9.1 OVERVIEW 103 9.2 COMPETITIVE ANALYSIS 103 9.3 COMPETITIVE BENCHMARKING 104 9.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 105 9.5 MAJOR GROWTH STRATEGY IN THE GLOBAL INTRACRANIAL HEMORRHAGE DIAGNOSIS & TREATMENT MARKET 105 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 106 9.6.1 PRODUCT APPROVALS 106 9.6.2 ACQUISITIONS 106 9.6.3 AGREEMENTS/COLLABORATIONS 106 10 COMPANY PROFILES 10.1 CANON INC. 107 10.1.1 COMPANY OVERVIEW 107 10.1.2 FINANCIAL OVERVIEW 108 10.1.3 PRODUCTS/SERVICES OFFERED 109 10.1.4 KEY DEVELOPMENTS 109 10.1.5 SWOT ANALYSIS 110 10.1.6 KEY STRATEGIES 110 10.2 FUJIFILM CORPORATION 111 10.2.1 COMPANY OVERVIEW 111 10.2.2 FINANCIAL OVERVIEW 112 10.2.3 PRODUCTS/SERVICES OFFERED 112 10.2.4 KEY DEVELOPMENTS 112 10.2.5 SWOT ANALYSIS 113 10.2.6 KEY STRATEGIES 113 10.3 GE HEALTHCARE 114 10.3.1 COMPANY OVERVIEW 114 10.3.2 FINANCIAL OVERVIEW 115 10.3.3 PRODUCTS/SERVICES OFFERED 116 10.3.4 KEY DEVELOPMENTS 116 10.3.5 SWOT ANALYSIS 117 10.3.6 KEY STRATEGIES 117 10.4 HITACHI, LTD 118 10.4.1 COMPANY OVERVIEW 118 10.4.2 FINANCIAL OVERVIEW 118 10.4.3 PRODUCTS/SERVICES OFFERED 119 10.4.4 KEY DEVELOPMENTS 119 10.4.5 SWOT ANALYSIS 120 10.4.6 KEY STRATEGIES 120 10.5 INFRASCAN, INC. 121 10.5.1 COMPANY OVERVIEW 121 10.5.2 FINANCIAL OVERVIEW 121 10.5.3 PRODUCTS/SERVICES OFFERED 121 10.5.4 KEY DEVELOPMENTS 121 10.5.5 SWOT ANALYSIS 122 10.5.6 KEY STRATEGIES 122 10.6 JOHNSON & JOHNSON 123 10.6.1 COMPANY OVERVIEW 123 10.6.2 FINANCIAL OVERVIEW 123 10.6.3 PRODUCTS/SERVICES OFFERED 124 10.6.4 KEY DEVELOPMENTS 124 10.6.5 SWOT ANALYSIS 125 10.6.6 KEY STRATEGIES 125 10.7 KONINKLIJKE PHILIPS NV 126 10.7.1 COMPANY OVERVIEW 126 10.7.2 FINANCIAL OVERVIEW 127 10.7.3 PRODUCTS/SERVICES OFFERED 128 10.7.4 KEY DEVELOPMENTS 128 10.7.5 SWOT ANALYSIS 129 10.7.6 KEY STRATEGIES 129 10.8 MEDTRONIC PLC 130 10.8.1 COMPANY OVERVIEW 130 10.8.2 FINANCIAL OVERVIEW 130 10.8.3 PRODUCTS/SERVICES OFFERED 131 10.8.4 KEY DEVELOPMENTS 131 10.8.5 SWOT ANALYSIS 132 10.8.6 KEY STRATEGIES 132 10.9 SIEMENS 133 10.9.1 COMPANY OVERVIEW 133 10.9.2 FINANCIAL OVERVIEW 134 10.9.3 PRODUCTS/SERVICES OFFERED 135 10.9.4 KEY DEVELOPMENTS 135 10.9.5 SWOT ANALYSIS 136 10.9.6 KEY STRATEGIES 136 10.10 STRYKER 137 10.10.1 COMPANY OVERVIEW 137 10.10.2 FINANCIAL OVERVIEW 137 10.10.3 PRODUCTS/SERVICES OFFERED 138 10.10.4 KEY DEVELOPMENTS 138 10.10.5 SWOT ANALYSIS 139 10.10.6 KEY STRATEGIES 139 11 APPENDIX 11.1 REFERENCES 140 11.2 RELATED REPORTS 140

Related products